Jiuzhou Pharmaceutical(SH:603456) Xin Lang Cai Jing·2025-09-01 06:24Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical experienced a stock price increase of 5.14%, reaching 19.02 CNY per share, with a trading volume of 594 million CNY and a turnover rate of 3.61%, resulting in a total market capitalization of 16.917 billion CNY [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates. The revenue composition is as follows: 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - Among the top circulating shareholders of Jiuzhou Pharmaceutical, a fund under China Europe Fund holds a significant position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 4.3884 million shares in the second quarter, now holding 13.4263 million shares, which accounts for 1.51% of the circulating shares. The estimated floating profit today is approximately 12.4865 million CNY [2] - The China Europe Medical Health Mixed A Fund (003095) was established on September 29, 2016, with a current scale of 15.638 billion CNY. Year-to-date returns are 28.82%, ranking 2520 out of 8254 in its category; the one-year return is 43.11%, ranking 3274 out of 8037; and since inception, the return is 122.33% [2] Group 3 - The fund managers of the China Europe Medical Health Mixed A Fund (003095) are Ge Lan and Zhao Lei. As of the report, Ge Lan has a cumulative tenure of 10 years and 219 days, with a total fund asset size of 39.908 billion CNY, achieving a best fund return of 125.88% and a worst return of -35.13% during her tenure. Zhao Lei has a tenure of 60 days, managing a fund asset size of 30.801 billion CNY, with a best return of 13.75% and a worst return of 13.59% during his tenure [3]